Tradestie Institutional Equity Comparison Engine · Market Close Nov 28, 2025

CLSD vs CHEK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CHEK Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–0 Matrix Metrics)

CHEK Overall Winner 6-Pillar Tally: CLSD 2 – 2 CHEK (2 Tie) Matrix Metrics: CLSD 0 – 6 CHEK

As of Nov 28, 2025, Check-Cap Ltd. (CHEK) is the stronger overall head-to-head candidate over Clearside Biomedical, Inc. (CLSD) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CLSD carries a Unified Composite Score of 43.3/100 (HOLD) at $0.41 (N/M Forward P/E, -3502.5% operating margin), whereas CHEK carries 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CLSD vs CHEK
CLSD NASDAQ
Clearside Biomedical, Inc. Common Stock
Pharmaceutical Preparations
$0.41
-26.96% 1D
Market Cap $2.9M
TTM Revenue $3.3M
Forward P/E N/M
Beta / 30D Vol 2.24β · 269% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 40.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 17
RSI-14: 17.4 · SMA20: $2.98 · SMA50: $3.60
CHEK NASDAQ Head-to-Head Winner
Check-Cap Ltd.
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$1.61
+1.9% 1D
Market Cap $9.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.94β · 179% Vol
Unified Composite Score
52.1 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 51.0 · SMA20: $1.52 · SMA50: $1.80

6-Pillar Scorecard Institutional Category Breakdown (CLSD 2 – 2 CHEK)

Columns: Metric · CLSD · CHEK
1. Valuation Multiples CLSD
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.9x N/M
2. Growth & Scale CHEK
Revenue Growth (YoY) -80.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $3.3M N/A
Market Cap $2.9M $9.2M
3. Profitability & Quality CHEK
Gross Margin 88.1% N/A
Operating Margin -3502.5% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -1310.0% -226.2%
4. Balance Sheet & Cash Flow CLSD
Cash Generation (TTM) -$23M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage -1310.0% ROE -226.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Pharmaceutical Preparations Operator X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CLSD (0) vs CHEK (6)
Institutional Metric CLSD CHEK Criterion Row Edge
Market Capitalization
Scale
$2.9M $9.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-80.6% +0.0% Higher Growth CHEK
Operating Margin (TTM)
Profitability
-3502.5% 0.0% Higher Margin CHEK
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-1310.0% -226.2% Higher ROE CHEK
52-Week Range Position
Momentum
1% ($0–$17) 41% ($1–$3) Stronger Trend CHEK
Beta / 30D Volatility
Risk Regime
2.24β · 269% Vol 0.94β · 179% Vol Lower Realized Risk CHEK
Unified Institutional Score
Composite Signal
43.3 / 100 (HOLD) 52.1 / 100 (HOLD) Higher Composite CHEK
Trailing 12M Revenue (USD)
Operating Scale
$3.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
88.1% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$23M EBITDA (-1310.0% ROE) N/A (-226.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CHEK +93.66 pp
CLSD: -85.61% · CHEK: +8.05%
3M Horizon CHEK +105.11 pp
CLSD: +44.89% · CHEK: +150.0%
6M Horizon CHEK +124.86 pp
CLSD: -28.04% · CHEK: +96.82%
1Y Horizon CHEK +193.43 pp
CLSD: -96.54% · CHEK: +96.89%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLSD vs CHEK. Trailing 12-month operating profitability (CLSD -3502.5% vs CHEK 0.0%) and valuation multiples (CLSD N/M vs CHEK N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CLSD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.3M
Gross Margin88.1%
Op. Margin-3502.5%
ROE / Fwd P/E-1310.0% · N/M
CHEK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-226.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CLSD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLSD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CHEK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CHEK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CLSD Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $2.9M market capitalization and -3502.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CHEK Moat Profile Cyclical / Execution-Driven Positioning
X-Ray Apparatus & Tubes & Related Irradiation Apparatus Operator
Competes within the X-Ray Apparatus & Tubes & Related Irradiation Apparatus value chain with $9.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CLSD vs CHEK Key Questions & Quantitative Answers

As of Nov 28, 2025, Check-Cap Ltd. (CHEK) is the stronger overall head-to-head candidate over Clearside Biomedical, Inc. (CLSD) in the Tradestie Institutional Equity Comparison Engine, winning 6–0 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CLSD carries a Unified Composite Score of 43.3/100 (HOLD) at $0.41 (N/M Forward P/E, -3502.5% operating margin), whereas CHEK carries 52.1/100 (HOLD) at $1.61 (N/M Forward P/E, 0.0% operating margin). Technically, CLSD sits in a Neutral phase (RSI 17.4, UNCLASSIFIED options structure) and CHEK sits in a Neutral phase (RSI 51.0, UNCLASSIFIED options structure).

CHEK leads the Growth & Scale pillar: CLSD posts -80.6% YoY revenue growth and +0.0% YoY earnings growth on $3.3M TTM revenue (88.1% gross margin, -3502.5% operating margin), compared with CHEK at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CLSD generates $3.3M in USD-normalized revenue versus N/A for CHEK. In operating R&D and SG&A reinvestment, CLSD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CHEK.

CLSD screens cheaper on headline valuation multiples. CLSD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (unreported EBITDA margin), whereas CHEK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLSD (-1310.0% ROE) versus CHEK (-226.2% ROE) capital efficiency.

In options market volatility and institutional positioning, CLSD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.24β · 269% Vol realized risk). By comparison, CHEK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 179% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 28, 2025. For educational research only; not investment advice.